Interventional Pulmonology Market Size & Share, by Product (Bronchoscopes, Airway Stents, Pleural Catheters, Biopsy Devices); Application; Procedure; End user; Technology - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2026-2035

Interventional Pulmonology Market - Regional Analysis

North America Market Insights

North America is poised to retain its leadership in the global interventional pulmonology market by holding the highest share of 38.7% during the analyzed timeline. The region is driven by the rising incidence of chronic respiratory diseases such as COPD, lung cancer, and severe asthma, and by the rising adoption of minimally invasive procedures. The NLM article released in December 2023 depicts that nearly 600 million cases of COPD are expected by 2050, compared with the past five years' COPD cases. On the other hand, the interventional pulmonology market is experiencing a rapid shift with advancements in technology, and has improved the accuracy of peripheral bronchoscopy by approximately 60% to 85%, as per the chest article released in 2025. This transformation highlights the demand for advanced pulmonary care.

The U.S. dominance over the regional interventional pulmonology market is primarily gained from high procedure volumes, fast technology adoption, and payer-enabled reimbursement pathways. Besides, the rapid adoption of AI bronchoscopy systems testifies to the technologically progressive atmosphere cultivated across the country, where the FDA has granted Breakthrough Device Designation for the NIO by Invenio Imaging, which is a lung cancer reveal image analysis to help physicians evaluate bronchoscopic lung forceps biopsies. The device has been used for more than 10,000 procedures in bronchoscopy, neurosurgery, and endoscopy.

Hospital Distribution by Annual Bronchoscopy Procedure Volume in the U.S.

Source: NLM

APAC Market Insights

The interventional pulmonology market is witnessing a rapid shift and is led by the increase in lung cancer programs, rising chronic respiratory diseases, and the fast adoption of minimally invasive therapeutic and diagnostic tools. China is leading the interventional pulmonology market due to its rising patient base, improvement in hospital infrastructure. Trends such as the integration of CT-derived navigation, EBUS-TBNA expansion for mediastinal staging, and increasing capital investment in bronchoscopy suites boost the APAC market. Further, as per the Non-Profit Organization, Asian Pacific Association for Bronchology and Interventional Pulmonology in 2025 report, the lung cancer screening programs rose to 51.2% due to people having high rates of smoking habits. Policy support is largely determining the market penetration by 2035.

India shows a rapid growth of interventional pulmonology as private hospitals in developed areas are rapidly adopting EBUS and navigational tools, whereas the public sector lags in expansion. Government health funding has increased over the last decade, and national cancer control programs are strengthening diagnostic pathways. The Amrita Hospitals report 2025 states that the hospital has performed 1500 rigid bronchoscopic therapeutic procedures and 4000 diagnostic bronchoscopic procedures to date. Further, advancements such as Bronchoscopic Thermal Vapour Ablation, which is an endoscopic lung volume reduction (ELVR) treatment, surge the adoption rate in the country for improved respiratory mechanics.

Import data of spirometers, ventilators, CPAP/BiPAP machines, pulse oximeters, and bronchoscopes

Source: WITS

Europe Market Insights

Europe is predicted to augment its position as the second-largest shareholder in the global interventional pulmonology market consistently by the end of 2035. The region is driven by the rising aging populations, lung-cancer screening uptake, and greater investment in minimally invasive diagnostics and therapies. Additionally, the region-wide reimbursement reforms are ensuring maximum adoption in this sector by providing adequate financial backing. In Europe, nearly 226,500 death cases are registed due to lung cancer, as per the Eurostat report in July 2024. This indicates the demand for procedural distribution across the region and innovations in robotic platforms in pulmonology sector.

Germany dominates the Europe interventional pulmonology market and is driven by the robust outpatient procedural capacity, dense hospital network, and early adoption of advanced bronchoscopy platforms. Prevalence of high lung cancer among older population, combined with organized screening expansions and strong referral pathways to sustain diagnostic volumes. Further, local manufacturing of the devices and clinical partnerships with hospitals surge the cost efficiencies. The NLM article released in June 2023 states that lung cancer cases have increased 68.5% to 93.8%, and reduced mortality rate of 15%. This is due to the rising pulmonology sector innovations.